Tekmira Inks siRNA Delivery Tech Deal with Pfizer, Reports Higher Q4 Losses on R&D Spending

"Tekmira will be responsible for preparing the SNALP formulations and Pfizer will evaluate the formulations in preclinical models," the companies said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.